Down 5.2% today, more than its drugmaker peers' 1.7%; no story names it yet.
Down
Down 74% in 3 months while the S&P 500 was flat.
−2Long-term trend
ALMS's Quality Score fell 1 point on Mon, Nov 2, to -8.
Follow ALMS's trial news. Pro members can get an alert when Alumis files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | 67.0% more shares than a year ago |
| Latest filing | 10-Q, Aug 13 |
TodayNo story names it yet.
After its last 4 reports it closed 0.0% on average, higher 2 of 4 times.
About 5 quarters
Director Srinivas Akkaraju bought 986,721 shares on Sep 8. 10 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
ALMS is #89 of 92 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 89 |
Expected to report Thu Nov 12, after the close (in 10 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The decrease was primarily driven by lower clinical trial and contract research costs following completion of enrollment and reporting of positive topline results for the pivotal Phase 3 ONWARD1 and ONWARD2 clinical trials of envudeucitinib in patients with PsO in January 2026 and severance costs related to the merger with ACELYRIN, Inc. in the quarter ended June 30, 2025, partially offset by an increase in clinical trial and contract research costs for the Phase 3 ONWARD3 clinical trial and an increase in personnel-related expenses for the quarter ended June 30, 2026.”
ALMS's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The decrease was primarily attributable to severance and transaction costs related to the merger with ACELYRIN, Inc. in the quarter ended June 30, 2025, partially offset by legal expenses and other costs and an increase in personnel-related expenses for the quarter ended June 30, 2026.”
From its results filing (SEC filing · Aug 13)
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 13, 2026 | -5.0% | +3.7% | -6.3% |
| May 14, 2026 | -8.4% | -7.2% | -10.0% |
| Mar 19, 2026 | -2.1% | -1.3% | +3.7% |
One insider bought $8.3M across 3 filings, and 7 insiders sold $1.5M across 9 filings, in the last 6 months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: ALMS is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
“The biopharmaceutical industry is characterized by intense competition and rapid innovation.”
ALMS scores -8 today, which Breakaway calls Poor. It is #89 of 92 in Pharma by Quality Score, with 0 of 14 chart checks firing. Down 74% in 3 months while the S&P 500 was flat. Cash lasts about 5 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ALMS scores -8 today, which Breakaway calls Poor (below zero). That is #89 of 92 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ALMS's -8.
One insider bought $8.3M across 3 filings, and 7 insiders sold $1.5M across 9 filings, in the last 6 months. The newest is Srinivas Akkaraju, Director, who bought $2.9M on Sep 8. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.